During the prescribed-use period:
After the prescribed-use period:
NIDA (NIH) has awarded us a grant to advance XpiRx through IND-enabling studies. We have identified our lead and backup candidates for upcoming non-clinical and clinical studies. We believe that this technology could become commercially available in the 2021-timeframe.
Our O2P opioids are designed to provide the following unprecedented features:
With the support of NIH/NIDA, we have demonstrated in vivo proof of concept for this program (see below), and have identified lead compounds for progression to non-clinical and clinical studies. The first product could be on the market in the 2021-timeframe.